Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 217

1.

Tumor size and postoperative kidney function following radical nephrectomy.

Ellis RJ, White VM, Bolton DM, Coory MD, Davis ID, Francis RS, Giles GG, Gobe GC, Neale RE, Wood ST, Jordan SJ.

Clin Epidemiol. 2019 May 6;11:333-348. doi: 10.2147/CLEP.S197968. eCollection 2019.

PMID:
31191028
2.

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.

Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Tu E, Vera-Badillo F, Williams SG, Yip S, Zhang AY, Zielinski RR, Sweeney CJ; ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group.

N Engl J Med. 2019 Jun 2. doi: 10.1056/NEJMoa1903835. [Epub ahead of print]

PMID:
31157964
3.

Prognostic Utility of a Whole-blood Androgen Receptor-based Gene Signature in Metastatic Castration-resistant Prostate Cancer.

Kwan EM, Fettke H, Docanto MM, To SQ, Bukczynska P, Mant A, Pook D, Ng N, Graham LK, Mangiola S, Segelov E, Mahon K, Davis ID, Parente P, Pezaro C, Todenhöfer T, Horvath LG, Azad AA.

Eur Urol Focus. 2019 May 15. pii: S2405-4569(19)30139-7. doi: 10.1016/j.euf.2019.04.020. [Epub ahead of print]

PMID:
31103601
4.

Circulating Estrogen Receptor Mutations and Splice Variants in Advanced Prostate Cancer.

Qu LG, Wardan H, Davis ID, Iddawela M, Sluka P, Pezaro CJ.

BJU Int. 2019 May 15. doi: 10.1111/bju.14797. [Epub ahead of print]

PMID:
31090242
5.

Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.

Stukalin I, Wells JC, Graham J, Yuasa T, Beuselinck B, Kollmansberger C, Ernst DS, Agarwal N, Le T, Donskov F, Hansen AR, Bjarnason GA, Srinivas S, Wood LA, Alva AS, Kanesvaran R, Fu SYF, Davis ID, Choueiri TK, Heng DYC.

Curr Oncol. 2019 Apr;26(2):e175-e179. doi: 10.3747/co.26.4595. Epub 2019 Apr 1.

6.

Incident Chronic Kidney Disease After Radical Nephrectomy for Renal Cell Carcinoma.

Ellis RJ, White VM, Bolton DM, Coory MD, Davis ID, Francis RS, Giles GG, Gobe GC, Marco DJT, Neale RE, Wood ST, Jordan SJ; IMPROVE Investigators.

Clin Genitourin Cancer. 2019 Jun;17(3):e581-e591. doi: 10.1016/j.clgc.2019.02.011. Epub 2019 Mar 15.

PMID:
30975606
7.

The contribution of multiparametric pelvic & whole body MR to interpretation of 18F-fluoromethylcholine or 68Ga-HBED-CC PSMA-11 PET/CT in patients with biochemical failure following radical prostatectomy.

Metser U, Chua SS, Ho B, Punwani S, Johnston E, Pouliot F, Tau N, Hawsawy A, Anconina R, Bauman G, Hicks RJ, Weickhardt A, Davis ID, Pond G, Scott A, Tunariu N, Sidhu H, Emmett LM.

J Nucl Med. 2019 Mar 22. pii: jnumed.118.225185. doi: 10.2967/jnumed.118.225185. [Epub ahead of print]

PMID:
30902875
8.

Assessment of simplified methods for quantification of 18F-FDHT uptake in patients with metastatic castration-resistant prostate cancer.

Kramer GM, Yaqub M, Vargas HA, Schuit R, Windhorst AD, van den Eertwegh A, van der Veldt A, Bergman A, Burnazi E, Lewis JS, Chua SS, Staton K, Beattie BJ, Humm JL, Davis ID, Weickhardt A, Scott A, Morris MJ, Hoekstra OS, Lammertsma AA.

J Nucl Med. 2019 Mar 8. pii: jnumed.118.220111. doi: 10.2967/jnumed.118.220111. [Epub ahead of print]

PMID:
30850488
9.

What Survival Benefits are Needed to Make Adjuvant Sorafenib Worthwhile After Resection of Intermediate- or High-Risk Renal Cell Carcinoma? Clinical Investigators' Preferences in the SORCE Trial.

Lawrence NJ, Martin A, Davis ID, Troon S, Sengupta S, Hovey E, Coskinas X, Kaplan R, Smith B, Ritchie A, Meade A, Eisen T, Blinman P, Stockler MR.

Kidney Cancer. 2018 Aug 1;2(2):123-131. doi: 10.3233/KCA-180038.

10.
11.

Clinical Trials of Metastatic Castration-sensitive Prostate Cancer: Recent Progress and New Horizons.

Hamid AA, Morris MJ, Davis ID.

Eur Urol Focus. 2019 Mar;5(2):165-167. doi: 10.1016/j.euf.2018.12.001. Epub 2018 Dec 14.

PMID:
30559064
12.

Prospective, Multisite, International Comparison of 18F-Fluoromethylcholine PET/CT, Multiparametric MRI, and 68Ga-HBED-CC PSMA-11 PET/CT in Men with High-Risk Features and Biochemical Failure After Radical Prostatectomy: Clinical Performance and Patient Outcomes.

Emmett L, Metser U, Bauman G, Hicks RJ, Weickhardt A, Davis ID, Punwani S, Pond G, Chua S, Ho B, Johnston E, Pouliot F, Scott AM.

J Nucl Med. 2019 Jun;60(6):794-800. doi: 10.2967/jnumed.118.220103. Epub 2018 Nov 15.

PMID:
30442757
13.

Good clinical practice can and must include comparative effectiveness research.

Zeps N, Davis ID, Mark S.

BJU Int. 2018 Nov;122 Suppl 5:7-8. doi: 10.1111/bju.14590. Epub 2018 Nov 13. No abstract available.

14.

Exploring the spectrum of late effects following radical orchidectomy for stage I testicular seminoma: a systematic review of the literature.

Soon JA, Anton A, Torres J, Lawrence R, Parente P, McKendrick J, Davis ID, Pezaro C.

Support Care Cancer. 2019 Feb;27(2):373-382. doi: 10.1007/s00520-018-4492-7. Epub 2018 Oct 22.

PMID:
30350189
15.

Age at diagnosis and the surgical management of small renal carcinomas: findings from a cross-sectional population-based study.

White VM, Marco DJT, Bolton D, Papa N, Neale RE, Coory M, Davis ID, Wood S, Giles GG, Jordan SJ.

BJU Int. 2018 Nov;122 Suppl 5:50-61. doi: 10.1111/bju.14585.

16.

Protocol for the P3BEP trial (ANZUP 1302): an international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours.

Lawrence NJ, Chan H, Toner G, Stockler MR, Martin A, Yip S, Wong N, Yeung A, Mazhar D, Pashankar F, Frazier L, McDermott R, Walker R, Tan H, Davis ID, Grimison P; ANZUP.

BMC Cancer. 2018 Aug 29;18(1):854. doi: 10.1186/s12885-018-4745-3.

17.

Management of patients with advanced prostate cancer in the Asia Pacific region: 'real-world' consideration of results from the Advanced Prostate Cancer Consensus Conference (APCCC) 2017.

Chiong E, Murphy DG, Akaza H, Buchan NC, Chung BH, Kanesvaran R, Khochikar M, Letran J, Lojanapiwat B, Ng CF, Ong T, Pu YS, Saad M, Schubach K, Türkeri L, Umbas R, Le Chuyen V, Williams S, Ye DW; ANZUP Cancer Trials Group, Davis ID.

BJU Int. 2019 Jan;123(1):22-34. doi: 10.1111/bju.14489. Epub 2018 Aug 19. Review.

PMID:
30019467
18.

Active surveillance of men with low risk prostate cancer: evidence from the Prostate Cancer Outcomes Registry-Victoria.

Evans MA, Millar JL, Earnest A, Frydenberg M, Davis ID, Murphy DG, Kearns PA, Evans SM.

Med J Aust. 2018 Jun 4;208(10):439-443. Epub 2018 May 28.

PMID:
29793403
19.

Predictors of new-onset chronic kidney disease in patients managed surgically for T1a renal cell carcinoma: An Australian population-based analysis.

Ahn T, Ellis RJ, White VM, Bolton DM, Coory MD, Davis ID, Francis RS, Giles GG, Gobe GC, Hawley CM, Johnson DW, Marco DJT, McStea M, Neale RE, Pascoe EM, Wood ST, Jordan SJ; IMPROVE investigators.

J Surg Oncol. 2018 Jun;117(7):1597-1610. doi: 10.1002/jso.25037. Epub 2018 May 22.

PMID:
29790163
20.

Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial.

Guo J, Jin J, Oya M, Uemura H, Takahashi S, Tatsugami K, Rha SY, Lee JL, Chung J, Lim HY, Wu HC, Chang YH, Azad A, Davis ID, Carrasco-Alfonso MJ, Nanua B, Han J, Ahmad Q, Motzer R.

J Hematol Oncol. 2018 May 22;11(1):69. doi: 10.1186/s13045-018-0617-1.

21.

Interpolation to define clinical tumor stage in prostate cancer using clinical description of digital rectal examination.

Evans SM, Murphy DG, Davis ID, Sengupta S, Borzeshi EZ, Sampurno F, Millar JL.

Asia Pac J Clin Oncol. 2018 Oct;14(5):e412-e419. doi: 10.1111/ajco.12875. Epub 2018 Apr 27.

PMID:
29700974
22.

Reproducibility and Repeatability of Semiquantitative 18F-Fluorodihydrotestosterone Uptake Metrics in Castration-Resistant Prostate Cancer Metastases: A Prospective Multicenter Study.

Vargas HA, Kramer GM, Scott AM, Weickhardt A, Meier AA, Parada N, Beattie BJ, Humm JL, Staton KD, Zanzonico PB, Lyashchenko SK, Lewis JS, Yaqub M, Sosa RE, van den Eertwegh AJ, Davis ID, Ackermann U, Pathmaraj K, Schuit RC, Windhorst AD, Chua S, Weber WA, Larson SM, Scher HI, Lammertsma AA, Hoekstra OS, Morris MJ.

J Nucl Med. 2018 Oct;59(10):1516-1523. doi: 10.2967/jnumed.117.206490. Epub 2018 Apr 6.

23.

Answering Questions and Questioning Answers: More Evidence To Guide Decision-making About Chemohormonal Therapy in Metastatic Prostate Cancer.

Davis ID.

Eur Urol. 2018 Jun;73(6):856-858. doi: 10.1016/j.eururo.2018.02.020. Epub 2018 Mar 7. No abstract available.

PMID:
29525541
24.

Experiences of Australian men diagnosed with advanced prostate cancer: a qualitative study.

Chambers SK, Hyde MK, Laurie K, Legg M, Frydenberg M, Davis ID, Lowe A, Dunn J.

BMJ Open. 2018 Feb 17;8(2):e019917. doi: 10.1136/bmjopen-2017-019917.

25.

Patients' preferences for adjuvant sorafenib after resection of renal cell carcinoma in the SORCE trial: what makes it worthwhile?

Blinman PL, Davis ID, Martin A, Troon S, Sengupta S, Hovey E, Coskinas X, Kaplan R, Ritchie A, Meade A, Eisen T, Stockler MR.

Ann Oncol. 2018 Feb 1;29(2):370-376. doi: 10.1093/annonc/mdx715.

PMID:
29177440
26.

Early-onset baldness and the risk of aggressive prostate cancer: findings from a case-control study.

Papa NP, MacInnis RJ, English DR, Bolton D, Davis ID, Lawrentschuk N, Millar JL, Severi G, Hopper JL, Giles GG.

Cancer Causes Control. 2018 Jan;29(1):93-102. doi: 10.1007/s10552-017-0981-0. Epub 2017 Nov 14.

PMID:
29139043
27.

Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancer.

Pezaro CJ, Omlin A, Mastris K; ANZUP Consumer Advisory Panel, Attard G, Beer TM, Chi KN, Chowdhury S, Davis ID, Drake CG, de Bono JS, Efstathiou E, Gravis G, Higano CS, Hussain M, James N, Logothetis CJ, Morgans A, Parker C, Ryan CJ, Saad F, Sartor O, Small EJ, Sternberg CN, Sweeney CJ, Tannock I, Tombal B, Gillessen S.

Ann Oncol. 2017 Aug 1;28(8):1692-1694. doi: 10.1093/annonc/mdx312. No abstract available.

PMID:
28838209
28.

Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.

Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, Carver B, Castellano D, Chung BH, Clarke N, Daugaard G, Davis ID, de Bono J, Borges Dos Reis R, Drake CG, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng F, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Higano CS, James N, Kantoff P, Kellokumpu-Lehtinen PL, Khauli RB, Kramer G, Logothetis C, Maluf F, Morgans AK, Morris MJ, Mottet N, Murthy V, Oh W, Ost P, Padhani AR, Parker C, Pritchard CC, Roach M, Rubin MA, Ryan C, Saad F, Sartor O, Scher H, Sella A, Shore N, Smith M, Soule H, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Tannock I, Tombal B, Valdagni R, Wiegel T, Omlin A.

Eur Urol. 2018 Feb;73(2):178-211. doi: 10.1016/j.eururo.2017.06.002. Epub 2017 Jun 24.

29.

Trends in the surgical management of stage 1 renal cell carcinoma: findings from a population-based study.

White V, Marco DJT, Bolton D, Davis ID, Jefford M, Hill D, Prince HM, Millar JL, Winship IM, Coory M, Giles GG.

BJU Int. 2017 Nov;120 Suppl 3:6-14. doi: 10.1111/bju.13889. Epub 2017 Jun 9.

30.

Total and beverage-specific alcohol intake and the risk of aggressive prostate cancer: a case-control study.

Papa NP, MacInnis RJ, Jayasekara H, English DR, Bolton D, Davis ID, Lawrentschuk N, Millar JL, Pedersen J, Severi G, Southey MC, Hopper JL, Giles GG.

Prostate Cancer Prostatic Dis. 2017 Sep;20(3):305-310. doi: 10.1038/pcan.2017.12. Epub 2017 Apr 18.

PMID:
28417982
31.

BCG + Mitomycin trial for high-risk non-muscle-invasive bladder cancer: progress report and lessons learned.

Hayne D, Stockler M, McCombie SP, Lawrence N, Martin A, Sengupta S, Davis ID.

BJU Int. 2017 May;119 Suppl 5:55-57. doi: 10.1111/bju.13873. Review. No abstract available.

32.

Ejaculatory frequency and the risk of aggressive prostate cancer: Findings from a case-control study.

Papa NP, MacInnis RJ, English DR, Bolton D, Davis ID, Lawrentschuk N, Millar JL, Pedersen J, Severi G, Southey MC, Hopper JL, Giles GG.

Urol Oncol. 2017 Aug;35(8):530.e7-530.e13. doi: 10.1016/j.urolonc.2017.03.007. Epub 2017 Mar 27.

PMID:
28359743
33.

A pilot study of peripheral blood BDCA-1 (CD1c) positive dendritic cells pulsed with NY-ESO-1 ISCOMATRIX™ adjuvant.

Davis ID, Quirk J, Morris L, Seddon L, Tai TY, Whitty G, Cavicchiolo T, Ebert L, Jackson H, Browning J, MacGregor D, Wittke F, Winkels G, Alex R, Miloradovic L, Maraskovsky E, Chen W, Cebon J.

Immunotherapy. 2017 Mar;9(3):249-259. doi: 10.2217/imt-2016-0132. Epub 2017 Feb 10.

PMID:
28183192
35.

Mindfulness-Based Cognitive Therapy in Advanced Prostate Cancer: A Randomized Controlled Trial.

Chambers SK, Occhipinti S, Foley E, Clutton S, Legg M, Berry M, Stockler MR, Frydenberg M, Gardiner RA, Lepore SJ, Davis ID, Smith DP.

J Clin Oncol. 2017 Jan 20;35(3):291-297. doi: 10.1200/JCO.2016.68.8788. Epub 2016 Nov 21.

PMID:
27870567
36.

Challenges of data sharing: valuable but costly?

Davis ID.

Lancet Oncol. 2017 Jan;18(1):15-16. doi: 10.1016/S1470-2045(16)30564-2. Epub 2016 Nov 16. No abstract available.

PMID:
27864014
37.

Benefit from cytoreductive nephrectomy and the prognostic role of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma.

Day D, Kanjanapan Y, Kwan E, Yip D, Lawrentschuk N, Davis ID, Azad AA, Wong S, Rosenthal M, Gibbs P, Tran B.

Intern Med J. 2016 Nov;46(11):1291-1297. doi: 10.1111/imj.13202.

PMID:
27507629
38.

Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category.

Davis ID, Xie W, Pezaro C, Donskov F, Wells JC, Agarwal N, Srinivas S, Yuasa T, Beuselinck B, Wood LA, Ernst DS, Kanesvaran R, Knox JJ, Pantuck A, Saleem S, Alva A, Rini BI, Lee JL, Choueiri TK, Heng DYC.

Eur Urol. 2017 Jun;71(6):970-978. doi: 10.1016/j.eururo.2016.09.047. Epub 2016 Oct 19.

PMID:
27771126
39.

Posterior reversible encephalopathy syndrome mimicking brain metastases in a patient with metastatic transitional cell carcinoma.

Wong K, Lee M, Davis ID, Parente P, Mckendrick J, Pezaro C.

Asia Pac J Clin Oncol. 2017 Oct;13(5):e534-e536. doi: 10.1111/ajco.12510. Epub 2016 Oct 11.

PMID:
27726296
40.

Fully automated synthesis of [(18) F]fluoro-dihydrotestosterone ([(18) F]FDHT) using the FlexLab module.

Ackermann U, Lewis JS, Young K, Morris MJ, Weickhardt A, Davis ID, Scott AM.

J Labelled Comp Radiopharm. 2016 Aug;59(10):424-8. doi: 10.1002/jlcr.3417. Epub 2016 Jul 4.

41.

The role of mindfulness in distress and quality of life for men with advanced prostate cancer.

Chambers SK, Foley E, Clutton S, McDowall R, Occhipinti S, Berry M, Stockler MR, Lepore SJ, Frydenberg M, Gardiner RA, Davis ID, Smith DP.

Qual Life Res. 2016 Dec;25(12):3027-3035. Epub 2016 Jun 17.

42.

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.

Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, Halabi S, Nelson PS, Sartor O, Smith MR, Soule HR, Akaza H, Beer TM, Beltran H, Chinnaiyan AM, Daugaard G, Davis ID, De Santis M, Drake CG, Eeles RA, Fanti S, Gleave ME, Heidenreich A, Hussain M, James ND, Lecouvet FE, Logothetis CJ, Mastris K, Nilsson S, Oh WK, Olmos D, Padhani AR, Parker C, Rubin MA, Schalken JA, Scher HI, Sella A, Shore ND, Small EJ, Sternberg CN, Suzuki H, Sweeney CJ, Tannock IF, Tombal B.

Ann Oncol. 2016 May 2. pii: mdw180. [Epub ahead of print] No abstract available.

PMID:
27141017
43.

Quality of care achievements of the Prostate Cancer Outcomes Registry-Victoria.

Sampurno F, Earnest A, Kumari PB, Millar JL, Davis ID, Murphy DG, Frydenberg M, Kearns PA, Evans SM.

Med J Aust. 2016 May 2;204(8):319.

PMID:
27125808
44.

Author reply 'First, do no harm': managing the metabolic impacts of androgen deprivation in men with advanced prostate cancer.

Lomax AJ, Parente P, Gilfillan C, Livingston PM, Davis ID, Pezaro C.

Intern Med J. 2016 Apr;46(4):507-8. doi: 10.1111/imj.13035. No abstract available.

PMID:
27062210
45.

Development of Indicators to Assess Quality of Care for Prostate Cancer.

Nag N, Millar J, Davis ID, Costello S, Duthie JB, Mark S, Delprado W, Smith D, Pryor D, Galvin D, Sullivan F, Murphy ÁC, Roder D, Elsaleh H, Currow D, White C, Skala M, Moretti KL, Walker T, De Ieso P, Brooks A, Heathcote P, Frydenberg M, Thavaseelan J, Evans SM.

Eur Urol Focus. 2018 Jan;4(1):57-63. doi: 10.1016/j.euf.2016.01.016. Epub 2016 Feb 20.

PMID:
28753751
46.

Health-Related Quality of Life, Psychological Distress, and Sexual Changes Following Prostate Cancer: A Comparison of Gay and Bisexual Men with Heterosexual Men.

Ussher JM, Perz J, Kellett A, Chambers S, Latini D, Davis ID, Rose D, Dowsett GW, Williams S.

J Sex Med. 2016 Mar;13(3):425-34. doi: 10.1016/j.jsxm.2015.12.026. Epub 2016 Feb 4.

47.

Mycoplasma Infection Alters Cancer Stem Cell Properties in Vitro.

Gedye C, Cardwell T, Dimopoulos N, Tan BS, Jackson H, Svobodová S, Anaka M, Behren A, Maher C, Hofmann O, Hide W, Caballero O, Davis ID, Cebon J.

Stem Cell Rev. 2016 Feb;12(1):156-61. doi: 10.1007/s12015-015-9630-8.

PMID:
26514153
48.

Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies.

Bellmunt J, Kheoh T, Yu MK, Smith MR, Small EJ, Mulders PF, Fizazi K, Rathkopf DE, Saad F, Scher HI, Taplin ME, Davis ID, Schrijvers D, Protheroe A, Molina A, De Porre P, Griffin TW, de Bono JS, Ryan CJ, Oudard S.

Eur Urol. 2016 May;69(5):924-32. doi: 10.1016/j.eururo.2015.10.021. Epub 2015 Oct 24.

49.

Patterns of care for metastatic renal cell carcinoma in Australia.

Day D, Kanjanapan Y, Kwan E, Yip D, Lawrentschuk N, Andrews M, Davis ID, Azad AA, Rosenthal M, Wong S, Johnstone A, Gibbs P, Tran B.

BJU Int. 2015 Oct;116 Suppl 3:36-41. doi: 10.1111/bju.13176. Epub 2015 Jul 21.

50.

Development of a Standardized Set of Patient-centered Outcomes for Advanced Prostate Cancer: An International Effort for a Unified Approach.

Morgans AK, van Bommel AC, Stowell C, Abrahm JL, Basch E, Bekelman JE, Berry DL, Bossi A, Davis ID, de Reijke TM, Denis LJ, Evans SM, Fleshner NE, George DJ, Kiefert J, Lin DW, Matthew AG, McDermott R, Payne H, Roos IA, Schrag D, Steuber T, Tombal B, van Basten JP, van der Hoeven JJ, Penson DF; Advanced Prostate Cancer Working Group of the International Consortium for Health Outcomes Measurement.

Eur Urol. 2015 Nov;68(5):891-8. doi: 10.1016/j.eururo.2015.06.007. Epub 2015 Jun 28.

Supplemental Content

Loading ...
Support Center